Incyte (INCY) Stock Price, News & Analysis

Company Overview

Incyte Corporation is a biopharmaceutical company focused on discovering, developing and commercializing medicines for serious diseases, with an emphasis on oncology, hematology and inflammatory or dermatologic conditions. The company conducts research through internal programs and collaborations with academic institutions, biotechnology companies and pharmaceutical partners.

Incyte’s marketed portfolio includes Jakafi (ruxolitinib), a JAK inhibitor used in the United States for certain myelofibrosis, polycythemia vera and graft-versus-host disease indications, and Opzelura (ruxolitinib) cream for certain inflammatory skin conditions. Its portfolio also includes Pemazyre (pemigatinib), a targeted therapy for selected cancers with specific fibroblast growth factor receptor alterations. Incyte continues to develop additional therapies in oncology, immunology and dermatology.

Founded in 1991, Incyte is headquartered in Wilmington, Delaware, and serves patients in the United States and international markets through its own commercial operations and partnerships. The company’s products may be marketed under different brand names or by collaborators outside the United States. Incyte is led by President and Chief Executive Officer Hervé Hoppenot.

Key Stats

• Today's Range: $107.83 to $112.06
• 50-Day Range: $108.62 to $129.72
• 52-Week Range: $84.02 to $132.60
• Volume: 1.87 million shs
• Average Volume: 1.78 million shs
• Market Capitalization: $22.62 billion
• P/E Ratio: 13.68
• Dividend Yield: N/A
• Price Target: $128.20
• Consensus Rating: Moderate Buy

Incyte Stock Analysis - MarketRank™

Incyte scored higher than 78% of companies evaluated by MarketBeat, and ranked 119th out of 873 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Incyte has received a consensus rating of Moderate Buy. The company's average rating score is 2.52, and is based on 1 strong buy rating, 11 buy ratings, 13 hold ratings, and no sell ratings.

Upside Potential

Incyte has a consensus price target of $128.20, representing about 14.9% upside from its current price of $111.57.

Amount of Analyst Coverage

Incyte has been the subject of 22 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 3.1 / 5
• Proj. Earnings Growth: 217.50%

Earnings Growth

Earnings for Incyte are expected to grow by 217.50% in the coming year, from $2.40 to $7.62 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Incyte is 13.68, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 40.79.

Price to Earnings Ratio vs. Sector

The P/E ratio of Incyte is 13.68, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 195.97.

Price to Earnings Growth Ratio

Incyte has a PEG Ratio of 3.68. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Incyte has a P/B Ratio of 4.24. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.88% of the float of Incyte has been sold short.

Short Interest Ratio / Days to Cover

Incyte has a short interest ratio ("days to cover") of 6.06.

Change versus previous month

Short interest in Incyte has recently increased by 0.06%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Incyte does not currently pay a dividend.

Dividend Growth

Incyte does not have a long track record of dividend growth.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: 0.32

News Sentiment

Incyte has a news sentiment score of 0.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.71 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 14 news articles for Incyte this week, compared to 8 articles on an average week.

Search Interest

22 people have searched for INCY on MarketBeat in the last 30 days. This is an increase of 144% compared to the previous 30 days.

MarketBeat Follows

6 people have added Incyte to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 2.0 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Incyte insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $6,361,428.00 in company stock.

Percentage Held by Insiders

16.20% of the stock of Incyte is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

96.97% of the stock of Incyte is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 7/28/2026
• Today: 10/14/2026
• Next Earnings (Estimated): 10/29/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:INCY
• CIK: 879169
• Web: www.incyte.com
• Phone: (302) 498-6700
• Fax: 302-425-2750
• Employees: 2,844
• Year Founded: 1991

Price Target and Rating

• Average Price Target for Incyte: $128.20
• High Price Target: $157.00
• Low Price Target: $90.00
• Potential Upside/Downside: +14.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.52
• Research Coverage: 25 Analysts

Profitability

• EPS (Trailing Twelve Months): $7.85
• Trailing P/E Ratio: 13.68
• Forward P/E Ratio: 46.49
• P/E Growth: 3.68
• Net Income: $1.29 billion
• Net Margins: 27.71%
• Pretax Margin: 33.81%
• Return on Equity: 29.93%
• Return on Assets: 22.88%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.59
• Quick Ratio: 4.51

Sales & Book Value

• Annual Sales: $5.14 billion
• Price / Sales: 4.40
• Cash Flow: $6.35 per share
• Price / Cash Flow: 17.58
• Book Value: $26.32 per share
• Price / Book: 4.24

Miscellaneous

• Outstanding Shares: 202,700,000
• Free Float: 169,861,000
• Market Cap: $22.62 billion
• Optionable: Optionable
• Beta: 0.74